HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Gilead Sciences

June 3, 2019 Off By BusinessWire

CHENGDU, China–(BUSINESS WIRE)–HitGen Inc. today announced that it has entered into a drug discovery
research collaboration with Gilead Sciences to identify potential small
molecule leads against targets of interest to Gilead. In this
collaboration, HitGen will apply its technology platform, based on
DNA-encoded library design, synthesis and interrogation, to discover
novel leads. Under the terms of the agreement, HitGen will receive an
undisclosed upfront payment and will be eligible for milestone payments
from Gilead.

“We are delighted to enter this collaboration with Gilead, an industry
leader in pharmaceutical research and development. We believe the
collaboration reinforces the role and reputation of HitGen’s platform in
the rapidly developing field of DNA-encoded chemistry. We will work
closely with Gilead scientists to generate new small-molecule lead
compounds for their research programs to help bring transformative
medicines to patients,” said Dr. Jin Li, Chairman of the Board and Chief
Executive Officer of HitGen.

About HitGen Inc.

HitGen is a rapidly growing biotech company with headquarters and
custom-built research facilities based in Chengdu, China, with a
subsidiary in the USA. HitGen has established an industry-leading
platform for early-stage drug discovery research centred on DNA encoded
chemical libraries (DELs). HitGen’s DELs include encoded syntheses for
more than 400 billion novel, diverse, drug-like small molecule and
macrocycle compounds. These compounds are members of DELs synthesised
from many hundreds of distinct chemical scaffolds, designed and
assembled with tractable chemistry based on proven results for
identifying drug-like leads against biological targets from known and
novel classes. HitGen is working with multiple pharmaceutical and
biotech companies, foundations and research institutes in North America,
Europe, Asia and Africa to discover and develop the novel therapeutics
of the future.

Contacts

For further information, please contact:
Dr. Jin Li, Chairman &
CEO, HitGen Inc. Tel: +86 28 85197385
Dr. Barry Morgan, Chief
Scientific Officer, HitGen Inc. Tel: +1 508 840 9646